Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

260 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma.
Takemura S, Kudo T, Asano R, Suzuki M, Tsumoto K, Sakurai N, Katayose Y, Kodama H, Yoshida H, Ebara S, Saeki H, Imai K, Matsuno S, Kumagai I. Takemura S, et al. Among authors: katayose y. Cancer Immunol Immunother. 2002 Mar;51(1):33-44. doi: 10.1007/s00262-001-0245-3. Epub 2002 Jan 11. Cancer Immunol Immunother. 2002. PMID: 11845258
A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity.
Yoshida H, Katayose Y, Unno M, Suzuki M, Kodama H, Takemura S, Asano R, Hayashi H, Yamamoto K, Matsuno S, Kudo T. Yoshida H, et al. Among authors: katayose y. Cancer Immunol Immunother. 2003 Feb;52(2):97-106. doi: 10.1007/s00262-002-0334-y. Epub 2003 Jan 18. Cancer Immunol Immunother. 2003. PMID: 12594573
A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells.
Hayashi H, Asano R, Tsumoto K, Katayose Y, Suzuki M, Unno M, Kodama H, Takemura S, Yoshida H, Makabe K, Imai K, Matsuno S, Kumagai I, Kudo T. Hayashi H, et al. Among authors: katayose y. Cancer Immunol Immunother. 2004 Jun;53(6):497-509. doi: 10.1007/s00262-003-0465-9. Epub 2003 Nov 25. Cancer Immunol Immunother. 2004. PMID: 14648071
260 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page